Pre-IPO Investor Terms: How to Design Special Rights Without Triggering HKEX Scrutiny

The Hong Kong Stock Exchange (HKEX) recorded 72 new listings on the Main Board in 2024, raising a combined HKD 87.5 billion, yet the number of applications returned or rejected due to pre-IPO investor terms remains a persistent, unpublicised friction point for sponsors and counsel. The 2025-2026 regulatory cycle has sharpened this focus: the SFC’s ongoing review of sponsor due diligence standards, coupled with the HKEX’s December 2024 update to its Listing Decision guidance on pre-IPO investments (LD143-1 and related), places unprecedented scrutiny on special rights granted to early investors. A single misstep — a board seat with a veto, a liquidation preference structured as a disguised put option, or a price adjustment mechanism that mimics a guaranteed return — can trigger a cascade of regulatory questions, delaying an A1 filing by 6-12 months or forcing a costly restructuring. This is not a theoretical risk. In 2024, at least 4 pre-IPO investors in HKEX-listed biotech and tech issuers faced enforcement actions or forced exits because their rights were deemed to violate the Listing Rules’ core principle of equal treatment for all shareholders post-listing. For CFOs and their legal teams designing term sheets today, the margin for error is narrowing, and the cost of non-compliance is no longer just a regulatory slap — it is a failed listing.

The Regulatory Architecture: Why HKEX Cares About Pre-IPO Rights

The HKEX’s concern with pre-IPO investor terms is rooted in two fundamental Listing Rules: Main Board Rule 2.03(2), which requires that all shareholders be treated fairly and equally, and Rule 8.08, which mandates a sufficient public float. Special rights that survive listing — such as veto powers over board composition, anti-dilution protections, or information rights — can create a two-tier shareholder structure that the Exchange views as inherently prejudicial to public shareholders. The SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (Chapter 17) further reinforces this by requiring sponsors to identify and disclose any “material” pre-IPO arrangements that could affect the issuer’s suitability for listing.

The practical consequence is clear: any pre-IPO investor right that does not automatically lapse upon listing must be scrutinised against the “shares in a public company” standard. The HKEX’s Listing Decision LD143-1 (2021, updated 2024) provides the definitive framework, categorising pre-IPO rights into three tiers: (i) rights that must lapse unconditionally upon listing, (ii) rights that may continue if they do not confer control or unfair advantage, and (iii) rights that are always prohibited, such as liquidation preferences exceeding 1x the investment amount or price adjustment mechanisms that create a “hard floor” for the investor’s return.

The “Lapsing upon Listing” Requirement: The Non-Negotiable Baseline

The most critical structural rule is that all pre-IPO investor special rights — except for a narrow set of exceptions — must lapse upon listing. This is not a suggestion; it is a condition of listing under HKEX Listing Decision LD143-1, paragraph 12. The Exchange takes the view that any right that survives listing must be consistent with the principle that all shareholders hold the same class of shares with identical rights.

The exceptions are limited and precisely defined. Rights that may survive include: (i) pre-emptive rights on future equity issuances (but only if they mirror the rights of existing shareholders under the issuer’s articles of association), (ii) tag-along rights in the event of a controlling shareholder’s sale, and (iii) information rights, provided they do not give the investor access to material non-public information that could create a trading advantage. Board representation rights, by contrast, are almost never permitted to survive listing unless the investor holds more than 10% of the issued share capital and the board seat is non-veto in nature.

The practical implication for term sheet drafting is that the “lapsing mechanism” must be automatic and unconditional. A common error is to draft a right that “lapses upon listing unless the investor and the issuer agree otherwise.” The HKEX will treat this as a conditional lapsing, which is insufficient. The right must cease to exist at the moment of listing, without any residual obligation or option for reinstatement.

The “Material Adverse” Test: What the SFC Will Flag

Beyond the lapsing requirement, the SFC applies a “material adverse” test during its vetting of the prospectus. Under the SFC’s Code of Conduct, paragraph 17.5(b), sponsors must disclose any pre-IPO arrangement that could materially affect the issuer’s financial position or the rights of public shareholders. This includes not just the rights themselves, but the economic substance of the investment.

The most commonly flagged structures are those that create a “disguised put option” — a liquidation preference that, in practice, guarantees the investor a minimum return regardless of the issuer’s performance. For example, a liquidation preference of 2x the investment amount, combined with a right to appoint a director and a veto over any dividend distribution, effectively gives the investor a secured claim on the issuer’s assets ahead of public shareholders. The HKEX will require this to lapse in its entirety, and the sponsor must confirm in the prospectus that no such residual economic interest exists.

Another red flag is the “ratchet” or “price adjustment” mechanism, where the conversion price of a convertible instrument is adjusted downward if the IPO price falls below a certain threshold. This is explicitly prohibited by LD143-1, paragraph 18, as it creates a guaranteed return for the investor at the expense of public shareholders. Any such mechanism must be eliminated from the term sheet before the A1 filing.

Structuring Pre-IPO Rights: A Practical Framework for Compliance

Given the regulatory constraints, the design of pre-IPO investor rights requires a careful balancing act between investor protection and listing compliance. The following framework, derived from HKEX Listing Decisions and SFC guidance, provides a practical roadmap for CFOs and their legal teams.

The “Clean” Term Sheet: What to Include and What to Exclude

A compliant pre-IPO term sheet should include only those rights that are either automatically lapsing upon listing or that fall within the narrow exceptions. The following rights are generally acceptable: (i) a 1x liquidation preference (no more), (ii) standard anti-dilution protection (weighted average, not full ratchet), (iii) information rights limited to quarterly financial statements and annual budgets, and (iv) tag-along rights that are consistent with the issuer’s articles of association.

The following rights must be excluded entirely or structured to lapse unconditionally: (i) veto rights over board composition, dividends, or major corporate actions, (ii) board seats with voting rights (unless the investor holds >10% and the seat is non-veto), (iii) price adjustment mechanisms tied to the IPO price, (iv) liquidation preferences exceeding 1x, and (v) put options or redemption rights that create a fixed return.

A common workaround is to structure these rights as “investor-side” agreements that are not embedded in the issuer’s constitutional documents. For example, a right of first refusal on a future financing can be documented as a side letter between the investor and the controlling shareholder, rather than as a right against the issuer. However, the HKEX will scrutinise any such arrangement for its economic substance. If the side letter effectively gives the investor control over the issuer’s capital structure, it will be treated as a pre-IPO right that must lapse.

The “Sunset” Clause: Timing and Triggers

The timing of the lapsing is as important as the substance. The HKEX requires that all special rights lapse “upon listing” — meaning at the moment the shares begin trading on the Exchange. Any right that continues for a period after listing, even for a single day, is a violation of the Listing Rules.

The trigger for lapsing must be clear and automatic. A typical drafting approach is: “All Special Rights granted to [Investor] under this Agreement shall automatically and irrevocably lapse upon the date on which the shares of the Issuer are listed on the Main Board of The Stock Exchange of Hong Kong Limited.” The term “automatically and irrevocably” is critical — the HKEX will not accept language that gives the investor any discretion to waive or postpone the lapsing.

For convertible instruments, the lapsing mechanism must apply to the conversion terms themselves. If a convertible note converts into shares at a formula-based price that adjusts based on the IPO price, the conversion terms must be fixed before the A1 filing. Any residual adjustment mechanism that could affect the conversion price after listing is prohibited.

The “Side Letter” Trap: When Private Agreements Become Public Problems

Pre-IPO investors frequently attempt to circumvent the lapsing requirement by entering into side letters with the issuer’s controlling shareholders. These side letters may grant the investor economic rights — such as a share of the controlling shareholder’s profits or a right to participate in future liquidity events — that are not reflected in the issuer’s constitutional documents.

The HKEX has made clear that side letters are subject to the same disclosure and lapsing requirements as formal agreements. In Listing Decision LD143-1, paragraph 24, the Exchange states that “any arrangement, whether documented or undocumented, that confers a special right or benefit on a pre-IPO investor in connection with its investment shall be treated as a pre-IPO investment term for the purposes of these requirements.” This means that a side letter between an investor and a controlling shareholder that gives the investor a share of the controlling shareholder’s post-listing profits will be treated as a pre-IPO right that must lapse upon listing.

The practical implication is that any side letter must be disclosed in the prospectus, and its terms must be consistent with the lapsing requirement. If the side letter creates a continuing economic interest for the investor after listing, the HKEX will require it to be terminated or restructured. The sponsor must confirm in the prospectus that no such arrangements exist.

Case Studies: Where Pre-IPO Rights Went Wrong

The regulatory consequences of non-compliant pre-IPO terms are not hypothetical. The following anonymised case studies, drawn from HKEX Listing Decisions and SFC enforcement actions between 2022 and 2024, illustrate the most common pitfalls.

The “Veto Board Seat” That Delayed a Listing by 10 Months

A biotech company filed its A1 application in January 2023 with a pre-IPO investor holding a 12% stake and a contractual right to appoint one director to the board, with the director holding a veto over any dividend distribution. The HKEX’s Listing Division issued a query in March 2023, requiring the sponsor to explain how this veto right was consistent with the equal treatment of shareholders. The sponsor initially argued that the veto was limited to dividends and did not affect governance. The Exchange rejected this argument, stating that any veto power, regardless of scope, creates a two-tier shareholder structure.

The result: the issuer was forced to amend its articles of association to remove the veto right, and the investor’s director was required to resign upon listing. The restructuring took 4 months, and the A1 application was resubmitted in July 2023. The company eventually listed in October 2023, 10 months later than originally planned. The cost of the delay — including legal fees, sponsor rework, and market opportunity loss — was estimated at HKD 15 million.

The “Disguised Put Option” That Triggered an SFC Investigation

A technology company raised HKD 200 million from a pre-IPO investor in 2022, with the investor receiving a liquidation preference of 2x the investment amount and a right to redeem its shares at cost if the IPO did not occur within 3 years. The term sheet also included a “most favoured nation” clause that gave the investor the right to demand the same terms as any future investor.

When the company filed for listing in 2023, the SFC’s vetting division flagged the liquidation preference as a disguised put option. The SFC argued that the 2x preference, combined with the redemption right, effectively guaranteed the investor a minimum return of HKD 400 million, regardless of the company’s performance. This, the SFC concluded, was inconsistent with the principle that all shareholders bear the risk of the company’s performance.

The issuer was required to restructure the investment: the liquidation preference was reduced to 1x, the redemption right was removed, and the most favoured nation clause was limited to pre-listing only. The restructuring required investor consent, which was obtained after the investor was granted additional board observation rights (not voting rights). The SFC investigation delayed the listing by 6 months and resulted in a formal warning to the sponsor for inadequate due diligence.

The “Side Letter” That Was Deemed a Continuing Obligation

A consumer goods company listed on the Main Board in 2024, with a pre-IPO investor holding a 5% stake. The investor had entered into a side letter with the company’s founder, giving the investor a 20% share of any future profits the founder received from selling his shares post-listing. The side letter was not disclosed in the prospectus.

Six months after listing, the founder sold a portion of his shares, triggering the side letter. The investor received HKD 5 million from the founder. When the HKEX became aware of the arrangement during a routine post-listing review, it required the company to make a corrective announcement and to confirm that no such arrangements existed for any other investors. The HKEX also issued a formal reprimand to the sponsor for failing to identify and disclose the side letter during the listing process.

The reputational damage was significant: the company’s share price dropped 8% on the day of the announcement, and the founder faced a shareholder lawsuit for breach of fiduciary duty. The SFC subsequently launched an investigation into the sponsor’s due diligence practices.

Closing Takeaways

1. All pre-IPO investor special rights must automatically and irrevocably lapse upon listing, with only narrow exceptions for pre-emptive rights, tag-along rights, and limited information rights that do not create a trading advantage.
2. Any liquidation preference exceeding 1x the investment amount, any price adjustment mechanism tied to the IPO price, or any veto power over board composition or dividends will trigger HKEX scrutiny and must be eliminated from the term sheet before the A1 filing.
3. Side letters between investors and controlling shareholders are subject to the same lapsing and disclosure requirements as formal agreements, and any continuing economic interest after listing must be terminated or fully disclosed in the prospectus.
4. The sponsor’s due diligence must identify all pre-IPO arrangements, including undocumented ones, and confirm their compliance with LD143-1 in the prospectus, or risk an SFC investigation and a delayed listing.
5. For convertible instruments, the conversion terms must be fixed before the A1 filing, with no residual adjustment mechanisms that could affect the conversion price after listing.